DRKS00008856已完成未知
Multicentre, prospective, randomised, blinded, placebo-controlled study to evaluate a novel medical device for long-lasting weight loss in overweight and obesity.
Praxis Dr. von Seck0 个研究点目标入组 21 人开始时间: 2015年7月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 95 Years(—)
- 性别
- All
入选标准
- •1.Age: 18 to 95 years
- •2.Gender: Männer und Frauen
- •3.BMI between 25 and 29.9 with concomitant obesity-related health disorders, an abdominal
- •fat distribution pattern, diseases which are aggravated by obesity or a high degree of psychosocial pressure.
- •4.BMI = 30 kg / m2
- •5.Capacity to consent
- •6.Signed consent form
- •7.Desire to reduce weight
- •8.Failure of a basic program (nutritional, exercise and behavioural therapy), i. e. less than 5% weight reductiom / 3 to 6 months or weight regain
排除标准
- •1.Weight reduction > 5% over the last months before inclusion into the study
- •2.Individuals with denture, esp. worn with implants or pivot teeth
- •3.Less than 10 teeth / joint, teeth with maximally mild to moderate paradontal Zähne pro Kiefer mit maximal leichter bis mittelschwerer paradontal defects
- •4.Craniomandibular problems
- •5.Wasting diseases
- •6.Clinical diagnosis of an eating disorder
- •7.Medication with substances influencing weight or appetite (i. e. steroids, psyotropic drugs, diuretics)
- •8.Major surgical interventions durign the last 3 months
- •9.Pregnancy or breastfeeding women
- •10.Mental disorders or non-compliance
- •11.Inability to take in meals on a regularly
- •12.Incapacity to give informed consent
- •13.Secondary causes of obesity, i.e. der Adipositas, wie hypothyrodism, cushings syndrome, hypogonadism, hypothalimic tumors, or metabolic decompensation in diabetes mellitus
- •14.Newly diagnosed diabetes mellitus during the last 6 months before inclusion
- •15.HbA1C > 9% in diabetics
- •16.Uncontrolled arterial hypertension
- •17.Initiation / change of medication for a chronic disease during the last 3 months before inclusion
- •18.Participation in another clinical trial
- •19.Participation in another weight reduction program in the last 3 months
- •20.Unintended weight loss in the last 3 months
- •21.Participation in another therapy program during the course of the study
研究者
相似试验
招募中
不适用
Multicentre, prospective, randomised, double-blind, placebo-controlled study to evaluate the mechanism of a novel medical device for long-lasting weight loss in overweight and obesity.E66.9Obesity, unspecifiedDRKS00008922Praxis Dr. med. von Seck15
进行中(未招募)
不适用
Prospective, randomised, multi-centre, blind-observer, controlled, parallel-group study comparing the efficacy and the safety of DERMAGEN® versus conventionnal treatment in the treatment of diabetic neuropthic foot ulcerDiabetic neuropathic foot ulcerMedDRA version: 12.0Level: LLTClassification code 10012664Term: Diabetic foot ulcerEUCTR2009-014276-22-CZaboratoires Genevrier388
进行中(未招募)
不适用
Prospective, randomised, multi-centre, blind-observer, controlled, parallel-group study comparing the efficacy and the safety of DERMAGEN® versus conventionnal treatment in the treatment of diabetic neuropthic foot ulcerDiabetic neuropathic foot ulcerMedDRA version: 12.0Level: LLTClassification code 10012664Term: Diabetic foot ulcerEUCTR2009-014276-22-PLaboratoires Genevrier388
已完成
不适用
Prospective, multicenter, randomized, controlled, single-blind other clinical trial. What is the efficacy of pelvic floor biofeedback training with ACTICORE1® for stress incontinence?N39.3Stress incontinenceDRKS00027319ACTICORE GmbH124
尚未招募
Unknown
Prospective, multicenter, randomized, controlled, single-blind other clinical trial. What is the efficacy of app-based biofeedback training with ACTICORE1® for female stress incontinence?N39.3Stress incontinenceDRKS00033971ACTICORE GmbH262
